Lung Cancer Biomarker Testing ECHO – Year 4

November 2024 - May 2025

Despite an unprecedented deployment of new effective treatment options for non-small cell lung cancer (NSCLC) that targets specific biomarkers, many patients face enormous challenges obtaining comprehensive biomarker testing. Participating health systems will gain the knowledge to address common barriers that exist within their cancer teams and institutions that preclude them from implementing NSCLC biomarker testing. This program will kick off in November of 2024, followed by six hour-long sessions between January and May 2025.

Our Experts

Bruce Johnson, MD, FASCO

Professor Emeritus, Harvard Medical School,
Physician Emeritus

Timothy Mullett, MD, MBA, FACS

Medical Director, Markey Cancer Center Network Development

Peter Baik, DO, FACOS, FACS

Thoracic Surgeon

Jared Christensen, MD

Clinical Assistant Professor, Radiology

Aakash Desai, MBBS, MPH

Assistant Professor Of Medicine
O'Neal Cancer Center

Cheri Erkmen, MD

Professor, Thoracic Medicine and Surgery
Director, Lung Cancer Screening Program

Adam Fox, MD

Assistant Professor, Department of Medicine

Missak Haigentz, Jr., MD

Chief of Thoracic Medical Oncology
Chief of Head & Neck Medical Oncology

Niharika Khanna, MD, MBBS, DGO

Associate Chair, Population Health Sciences

Abdul Rafeh Naqash, MD

Hematologist/Oncologist
TSET Phase I Clinical Trials Program

Koosha Paydary, MD, MPH, MSc

Assistant Professor, Department of Internal Medicine

Albert Rizzo, MD, FACP

Chief Medical Officer
American Lung Association

Gerard Silvestri, MD, MS

Hillenbrand Professor of Thoracic Oncology

Lynn Tanoue, MD, MBA

Professor of Medicine, Vice Chair of Clinical Affairs, Internal Medicine
Director, Lung Cancer Screening Program

Jonathan Villena Vargas, MD

Assistant Professor of Cardiothoracic Surgery, Attending Surgeon

Ignacio Wistuba, MD

Professor and Chair, Department of Translational Pathology